Modified B-type natriuretic peptide

Abstract

A modified B-type natriuretic peptide (BNP) is provided that comprises a covalently attached polymer comprising an amino acid, the polymer inhibiting degradation and / or clearance of BNP in a subject, and the modified BNP retains vasorelaxant activity. A nucleic acid molecule encoding the modified BNP as described above, as well as a vector comprising the nucleic acid molecule, and a cell comprising the vector. Also provided is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant agent. The method comprises administering the modified BNP to the subject. Further provided is a method of preparing the modified BNP as described above. Further provided is the use of the modified BNP as described above, the nucleic acid as described above, the vector as described above, and / or the cell as described above for the manufacture of a medicament for the treatment of a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant agent.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 188,743, filed May 14, 2021, and incorporated herein by reference in its entirety. [Background technology]

[0002] (1) Technical field The present application relates generally to therapeutic peptides. More specifically, the present invention relates to modified B-type natriuretic peptides (BNPs) that have reduced degradation and / or clearance in mammals.

[0003] (2) Description of related technology B-type natriuretic peptide (also known as brain natriuretic peptide (or "BNP"), sold commercially as nesiritide and NATRECOR®) is an endogenous peptide that belongs to the group of natriuretic peptides. BNP is a 32 amino acid peptide that was originally discovered in extracts of pig brain, hence the name brain natriuretic peptide. The description of the above protein can be found in the NCBI reference sequence NP_002512.1 ("Natriuretic peptide B preproprotein [Homo sapiens]"): It is provided as the mature protein listed in SPKMVQGSGC FGRKMDRISS SSGLGCKVLR RH (SEQ ID NO:1). It is present in the human brain, but in significantly higher amounts in ventricular tissue. BNP is released in response to increased myocardial wall stretch, which is excessively elevated in heart failure and is therefore used as a marker of pathology associated with high extracellular fluid volume.

[0004] Therapeutic measures related to sodium and water retention-related diseases are varied and include the administration of various diuretic substances. BNP has natriuretic, diuretic, vasorelaxant, and bronchodilatory effects and may have antagonistic effects on the renin-angiotensin-aldosterone system. It is understood that these peptides and their analogs (such as atrial natriuretic peptide (ANP), BNP, C-type natriuretic peptide (CNP), and urodilatin (Uro)) are effective in regulating blood pressure by controlling fluid volume and vascular diameter. In addition, these peptides provide anti-fibrotic and anti-inflammatory effects.

[0005] Several disease states are characterized by abnormal fluid retention, including congestive heart failure, cirrhosis, and nephrotic syndrome. These diseases are associated with excessive fluid accumulation in the venous side of the circulation and inadequate perfusion of the kidneys, leading to reduced glomerular filtration rate (GFR). Since 1980, the following advances have been made: BNP has been cloned and expressed, and a commercial product called nesiritide (or NATRECOR®) has been approved by the FDA for the clinical indication of managing acutely compensated congestive heart failure (ADHF). Nesiritide and related medical uses are described in US Pat. Nos. 5,993,131, 5,102,143, 5,111, 5,122,133, and 5,146,147. There are problems associated with the administration of nesiritide, including its short half-life in human subjects (see, e.g., O'Connor, 2011), and the product has not been adjusted to treat other cardiovascular, metabolic, renal, or pulmonary diseases other than chronic heart failure or ADHF.

[0006] More recently, a PEGylated BNP product described in WO 2009 / 156481 A1 is formulated to treat chronic heart failure, with peak plasma levels reaching 2-4 hours of continuous infusion. The PEGylated BNP described in that application is also immunogenic, creating problems with administration.

[0007] Thus, there is a need for modified BNP that has longer lasting blood levels and is also less immunogenic than PEGylated BNP. The present invention addresses that need. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] U.S. Pat. No. 5,114,923 [Patent Document 2] U.S. Patent No. 5,674,710 [Patent Document 3] U.S. Patent No. 6,586,396 [Patent Document 4] U.S. Pat. No. 6,974,861 [Patent Document 5] U.S. Patent No. 7,179,790 [Patent Document 6] International Publication No. 2009 / 156481A1 Summary of the Invention

[0009] Modified B-type natriuretic peptide (BNP) is provided that comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% amino acid sequence identity to SEQ ID NO: 1. In these embodiments, the modified BNP further comprises a covalently attached polymer comprising an amino acid, wherein the polymer inhibits degradation and / or clearance of BNP in the subject, and wherein the modified BNP retains vasorelaxant activity.

[0010] Also provided are nucleic acid molecules encoding the modified BNPs described above.

[0011] Further provided is a vector comprising the above-described nucleic acid molecule.

[0012] Further provided is a cell comprising the above-described vector.

[0013] Also provided is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant agent, comprising administering to a subject in need of such treatment a therapeutically effective amount of the modified BNP described above.

[0014] Additionally, methods of preparing the modified BNP described above are provided, which include expressing the modified BNP from the cells described above as a fusion protein that includes a polymer, or, alternatively, producing the BNP by solution or solid phase techniques and then covalently attaching the polymer using chemical methods.

[0015] Further provided is the use of the above-mentioned modified BNP, the above-mentioned nucleic acid, the above-mentioned vector, and / or the above-mentioned cell for the manufacture of a medicament for the treatment of a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant agent.

[0016] Those skilled in the art will understand that the drawings, described below, are for illustrative purposes only and are not intended to limit the scope of the present teachings in any way. [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 is a diagram of the structure of native BNP (SEQ ID NO:1). [Diagram 2] FIG. 1 is a general depiction of native BNP bound to its receptor. [Diagram 3] FIG. 1 is a diagram of the target sites of native BNP in relation to its enzymatic degradation. [Figure 4] 1 is a diagram of sites of interest for BNP derivatization, including PASylation. From left to right and top to bottom - SEQ ID NOs: 15, 16, 17, 18, 19, 20. [Diagram 5] FIG. 1 is a diagram of PAS-formed BNP and a method of production. [Figure 6] 1 is a graph depicting the results of an assay showing activation of the human natriuretic polypeptide receptor (hNPR1) by BNP and BNP derivatives. [Figure 7] FIG. 1 is a graph showing relaxation of precontracted guinea pig tracheal ring segments by BNP and the BNP derivative Compound 1. [Figure 8]FIG. 1 is a graph showing a two-phase model fit of dog plasma concentrations of Compound 1 over time following intravenous bolus administration (0.2 mg / kg). [Figure 9] FIG. 1 is a graph showing model fits of dog plasma concentrations of Compound 1 over time following subcutaneous bolus administration (0.9 mg / kg). [Figure 10] FIG. 1 shows graphs of 24 hour post-dose telemetry recordings of systolic blood pressure (SBP), diastolic blood pressure (DBP) and calculated mean arterial pressure (MAP=DBP+[0.33+(HR×0.0012)]×[SBP]) in dogs. [Figure 11] Graph showing 24 hour post-dosing telemetry recordings of mean arterial pressure (MAP) and heart rate (HR) following subcutaneous bolus administration of 0.9 mg / kg Compound 1 or vehicle. Mean data (N=3). [Figure 12] Graph showing 6-day recordings of mean arterial pressure (MAP) following subcutaneous administration of 0.9 mg / kg bolus of Compound 1, intravenous administration of 0.2 mg / kg bolus of Compound 1, and subcutaneous administration of vehicle (phosphate buffered saline). Mean data (N=3). [Figure 13] Graph showing 5-day recordings of mean arterial pressure (MAP) following subcutaneous bolus administration of 0.9 mg / kg Compound 1, plotted on the inverse axis (right side) to allow visualization of the correspondence with plasma concentrations of Compound 1. [Figure 14] 1 is a graph showing 5-day tracings of plasma cGMP concentrations following subcutaneous bolus administration of 0.9 mg / kg Compound 1 overlaid with corresponding plasma concentrations of Compound 1. [Figure 15] 1 is a graph showing the bioanalytical profile of compound 1 using size exclusion chromatography (A) and ESI mass spectrometry (B). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Abbreviations and definitions BNP: As used herein, the term "BNP" refers to B-type natriuretic peptide, which is described as a mature protein listed in the NCBI reference sequence NP_002512.1 "Natriuretic peptide B preproprotein [Homo sapiens]".

[0019] BNP protein: The term "BNP protein" or "BNP peptide" or "BNP polypeptide" refers to an expression product of the BNP gene, such as a native BNP protein, or a protein sharing at least 65% (preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) amino acid sequence identity with one of the above and exhibiting the functional activity of the native BNP protein. The term can include derivatives of BNP, including recombinant polypeptides covalently linked to one or both of the amino or carboxy termini of the BNP protein. Such recombinant proteins can be BNP proteins, including PASylated BNP proteins. The term can also include synthetic derivatives of BNP, having branched or unbranched polypeptide structures, for example, where the polypeptide is covalently linked to one or more of the amino acids that comprise the BNP protein. In both recombinant and synthetic aspects of the invention, the resulting polypeptides exhibit the biological activity of the native BNP protein.

[0020] The term "functional BNP protein" or "functional BNP" as used herein is intended to include a human BNP polypeptide having at least one functional activity of BNP.

[0021] Conservative Change: As used herein, when referring to a mutation in a nucleic acid molecule, a "conservative change" is one in which at least one codon in the protein-coding region of the nucleic acid is altered such that at least one amino acid in a polypeptide encoded by the nucleic acid sequence is replaced by another amino acid of like characteristics. Examples of conservative amino acid substitutions are: ser for ala, thr, or cys; lys for arg; gln for asn, his, or lys; his for asn; glu for asp or lys; asn for his or gln; asp for glu; pro for gly; leu for ile, phe, met, or val; val for ile or leu; ile for leu, met, or val; arg for lys; met for phe; tyr for phe or trp; thr for ser; trp for tyr; and phe for tyr.

[0022] Functional activity: As used herein, the term "functional activity" refers to the biological effect of a substance on a living cell or organism. Thus, the term "functional protein" or "functional peptide" or "functional polypeptide" as used herein relates to a protein or peptide or polypeptide that can induce, for example, the biological activity of BNP, e.g., its effectiveness in regulating blood pressure by controlling fluid volume and blood vessel diameter. In another example, the functional activity of a BNP protein can be identified as affecting abnormal fluid retention in a particular tissue. Methods for determining the biological activity of BNP, as well as fragments, variants and homologs of BNP, are provided herein. Those skilled in the art will recognize other methods of measuring BNP activity, e.g., heart failure and fluid retention activity. However, it should be noted that in the context of the present invention, the term "functional protein" relates to the entire protein of the present invention, or other branched or unbranched derivatives of the BNP protein, including both the amino acid sequence that has and / or mediates the biological activity and the amino acid sequence that forms a random coil conformation.

[0023] Thus, the term "functional amino acid sequence" as used herein may relate to the "first domain" of a functional protein of the invention, which mediates or has, or is capable of mediating or has, a biological activity as defined above. The term "amino acid sequence having and / or mediating biological activity" or "amino acid sequence having biological activity" also relates to the "functional polypeptide" of the invention, which relates to the "first domain" of said biologically active protein. The term "amino acid sequence having functional activity" also includes functional fragments of BNP, the half-life of which is increased while at the same time reducing immunogenic activity, either in vivo or in vitro. Thus, a protein having functional activity according to the present invention may comprise a functionally active amino acid sequence derived from a naturally produced polypeptide or a polypeptide produced by recombinant DNA technology.

[0024] Isolated Polypeptide: As used herein, the term "isolated polypeptide" means that a polypeptide molecule is present in a form other than that found naturally in its original environment with respect to association with other molecules. The term "isolated polypeptide" encompasses "purified polypeptide," which is used herein to mean that a particular polypeptide is in a substantially homogenous preparation that is substantially free of other cellular components, other polypeptides, viral material, or culture medium, or, when the polypeptide is chemically synthesized, is substantially free of chemical precursors or by-products associated with chemical synthesis. A "purified polypeptide" can be obtained from natural or recombinant host cells by standard purification techniques or by chemical synthesis.

[0025] The term "isolated polypeptide" also includes "recombinant polypeptide," and is used herein to mean a hybrid polypeptide produced by recombinant DNA techniques or chemical synthesis that has a particular polypeptide molecule covalently linked to one or more polypeptide molecules that are not naturally associated with the particular polypeptide.

[0026] PASylated or PASylated form: As used herein, the term "PASylated" or "PASylated form" is broadly defined to include BNP conjugated to a conformationally disordered polymeric sequence containing the amino acids Pro, Ala, and optionally Ser (each a "PAS" group). One skilled in the art will recognize that the PAS group may contain conservative substitutions, and the entire random coil containing Pro, Ala, and optionally Ser amino acids may also contain conservative substitutions. Thus, the term "PASylated" refers to the attachment of a solvated random chain with a large hydrodynamic volume to the BNP peptide. This amino acid string (polymer) adopts a bulky random coil structure, greatly increasing the size of the resulting modified peptide. By greatly increasing the size of the modified peptide, typically the rapid clearance of the biologically active component via renal filtration is delayed by one to two orders of magnitude. Similarly, the bulk of the random coil structure may prevent enzymatic degradation of the biologically active component.

[0027] Pharmaceutically acceptable: As used herein, the term "pharmaceutical acceptable" means approved by a regulatory agency of a federal or state government or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more particularly in humans.

[0028] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutical acceptable carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered. Such carriers may be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents. When the compound is administered intravenously, water is a preferred carrier. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. If desired, the compound can also be combined with minor amounts of wetting or emulsifying agents, or pH buffering agents such as acetates, citrates, or phosphates.Antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; and agents for adjusting tonicity such as sodium chloride or dextrose can also be carriers.The method of combining carriers to produce compositions is known to those skilled in the art.

[0029] Pharmaceutically acceptable salts: As used herein, "pharmaceutically acceptable salts" include salts of pharmaceutically acceptable compounds formed with free amino groups, such as those derived from hydrochloric, phosphoric, acetic, oxalic, and tartaric acids, and those formed with free carboxyl groups, such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, and procaine. When the compound is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic acid, benzenesulfonic acid (besylic acid), benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and the like. Besylic acid, hydrobromic acid, hydrochloric acid, phosphoric acid, and sulfuric acid are particularly preferred. If the compound is acidic, salts may be prepared from pharma- ceutically acceptable organic and inorganic bases. Suitable organic bases include, but are not limited to, lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine), and procaine. Suitable inorganic bases include, but are not limited to, alkaline and earth alkaline metals such as aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Methods for synthesizing such salts are known to those skilled in the art.

[0030] The terms "polypeptide", "protein" and "peptide" are used interchangeably herein to refer to an amino acid chain in which amino acid residues are linked by peptide bonds or modified peptide bonds. The amino acid chain can be any length of more than two amino acids. Unless otherwise specified, the terms "polypeptide", "protein" and "peptide" also encompass their various modified forms. Such modified forms can be naturally occurring modified forms or chemically modified forms. Examples of modified forms include, but are not limited to, glycosylated forms, phosphorylated forms, myristoylated forms, palmitoylated forms, ribosylated forms, acetylated forms, mimetics (Mason, 2010), and the like. Modifications also include intramolecular cross-linking and covalent attachment of various moieties such as lipids, flavins, biotin, polyethylene glycol or derivatives thereof. In addition, modifications can also include cyclization, branching, and cross-linking. Furthermore, amino acids other than the conventional 20 amino acids encoded by genes can also be included in a polypeptide.

[0031] The terms "protein" or "polypeptide" can also include "purified" polypeptides that are substantially separated from other polypeptides in the cell or organism in which the polypeptide naturally occurs (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 100% free of contaminants).

[0032] The terms "primer", "probe" and "oligonucleotide" may be used interchangeably herein to refer to relatively short nucleic acid fragments or sequences. They may be DNA, RNA, or hybrids thereof, or chemically modified analogs or derivatives thereof. Typically, they are single-stranded. However, they may also be double-stranded, with two complementary strands that may be separated and denatured. In certain embodiments, they are about 8 nucleotides to about 200 nucleotides, preferably about 12 nucleotides to about 100 nucleotides, more preferably about 18 to about 50 nucleotides in length. They may be labeled with a detectable marker or modified in any conventional manner for various molecular biology applications.

[0033] Random coil: As used herein, the term "random coil" relates to any conformation of a polymer molecule, including an amino acid polymer, in which the individual monomeric elements forming the polymeric structure are essentially randomly oriented towards adjacent monomeric elements while still being chemically bound to said adjacent monomeric elements. In particular, a polypeptide or amino acid polymer that adopts / has / forms a "random coil conformation" is substantially devoid of defined secondary and tertiary structure. The properties of polypeptide random coils and their methods of experimental identification are known to the skilled artisan and described in the scientific literature (Cantor (1980) Biophysical Chemistry, 2nd ed., WH Freeman and Company, New York; Creighton (1993) Proteins-Structures and Molecular Properties, 2nd ed., WH Freeman and Company, New York; Smith (1996) Fold Des I:R95-R106).

[0034] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" refers to an amount that, when administered to a particular subject, taking into account the nature and severity of that subject's disease or condition, has the desired therapeutic effect, e.g., an amount that cures, prevents, inhibits, or at least partially arrests or partially prevents the target disease or condition.

[0035] Transformed, transfected, or transgenic: A cell, tissue, or organism into which exogenous nucleic acid, such as a recombinant vector, has been introduced is considered to be "transformed," "transfected," or "transgenic." A "transgenic" or "transformed" cell or organism also includes the progeny of the cell or organism, including progeny produced from a breeding program that uses such a "transgenic" cell or organism as a breeding parent.

[0036] Treatment: As used herein in the context of modified BNP, the terms "treat", "treatment" and the like refer to the alleviation or alleviation of a pathological process mediated by the administration of modified BNP. In the context of the present invention, insofar as it relates to any of the other conditions listed below, the terms "treat", "treatment" and the like refer to the alleviation or alleviation of at least one symptom associated with such condition, or the slowing or reversal of the progression of such condition.

[0037] Vector: As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and / or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors."

[0038] Linker: The term "linker" refers to a short amino acid sequence that separates multiple domains of a polypeptide.

[0039] Methods involving conventional molecular biology techniques are generally known in the art and are described in detail in methodological articles such as Green and Sambrook (2012).

[0040] Modified B-type natriuretic peptide (BNP) Provided is BNP further comprising an amino acid polymer, e.g., a polymer of proline and alanine residues and optionally serine residues (PAS). Such compounds can be used to treat fibrotic diseases, including pulmonary diseases such as emphysema, asthma and COPD, inflammatory diseases, chronic heart failure and other abnormal fluid retention indications. In some embodiments, PASylation adds solvated random chains with large hydrodynamic volume to the native BNP protein. The addition of PAS polymers (PASylation) has been successfully utilized on 94 amino acid peptide Adnectins to increase plasma half-life (Aghaabdollahian, S. et al., 2019).

[0041] BNP1-32 has cysteines at residues 10 and 26 that form disulfide bridges, thus forming a loop structure in the central part of the hormone. Extending from these residues are linear head (N-terminal) and tail (C-terminal) portions (Figure 1).

[0042] Crystallographic data are available in which a fragment of the molecule from glycine at position 9, through the loop region to leucine at position 29, is co-crystallized with a receptor protein that closely resembles the target receptor. This data suggests that this portion of the molecule is likely buried within the receptor structure with little spare space. Further evidence for this comes from information derived from the entire 1-32 BNP molecule, whereby amphiphilic PEG oligomers attached to lysines at positions 14 and 27 lost agonist activity (Cataliotti et al., 2007).

[0043] The hormone is processed by cleavage between residues 2 and 3 by the enzyme DPPIV, between residues 4 and 5 by neprilysin, and between residues 7 and 8 by the metalloprotease meprin (Figure 3). When the amphiphilic PEG oligomer is attached to lysine at position 3, its activity is reasonably preserved and the half-life is extended. This suggests that at least a part of the head of the BNP molecule is not involved in receptor binding. Instead, the head of the BNP molecule occupies a region where there is space to accommodate macromolecules, presumably pointing away from the receptor binding site. Thus, the N-terminal region is an advantageous part of the BNP molecule to modify, including the processing point (e.g., the cleavage point in Figure 3) and residues that are not likely involved in receptor binding. However, the present invention encompasses PASylation of any point within the BNP molecule.

[0044] Thus, in some embodiments, a modified B-type natriuretic peptide (BNP) is provided. The modified BNP comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to SEQ ID NO:1, or a portion thereof. In these embodiments, the modified BNP further comprises a covalently attached polymer comprising amino acids, wherein the polymer inhibits degradation and / or clearance of BNP in a subject, and wherein the modified BNP retains vasorelaxant activity.

[0045] In some embodiments, the modified BNP has an altered sequence. These BNP protein variants, such as fragments, analogs, and derivatives of the native BNP protein, are also within the scope of the present invention. Such variants include, for example, polypeptides encoded by naturally occurring allelic variants of the native BNP gene, polypeptides encoded by alternative splice forms of the native BNP gene, polypeptides encoded by homologs of the native BNP gene, and polypeptides encoded by non-naturally occurring variants of the native BNP gene.

[0046] BNP protein variants have peptide sequences that differ from the native BNP protein in one or more amino acids. Such variant peptide sequences can be characterized by deletions, additions, or substitutions of one or more amino acids of the native BNP polypeptide. Amino acid insertions can be about 1, 2, 3, 4, 5, 6, 7, 8, and 9-10 consecutive amino acids, and deletions can be about 1, 2, 3, 4, 5, 6, 7, 8, and 9-10 consecutive amino acids. In some applications, the variant BNP protein substantially maintains the functional activity of the BNP protein. For other applications, the variant BNP protein lacks or is characterized by a significant reduction in the functional activity of the BNP protein. When it is desirable to retain the functional activity of the native BNP protein, preferred BNP protein variants can be made by expressing within the invention nucleic acid molecules characterized by silent or conservative changes. Variant BNP proteins with substantial changes in functional activity can be made by expressing within the invention nucleic acid molecules characterized by less than conservative changes.

[0047] BNP protein fragments and variants corresponding to one or more particular motifs and / or domains, or any size, for example, at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, and 32 amino acids in length, are intended to be within the scope of the present invention. Isolated peptidyl portions of BNP proteins can be obtained by screening peptides recombinantly produced from corresponding fragments of nucleic acids encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art, such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, the BNP protein of the present invention can be optionally divided into fragments of a desired length with no overlap of the fragments, or preferably, into overlapping fragments of a desired length. Fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments that can function as either agonists or antagonists of the native BNP protein.

[0048] Another aspect of the invention relates to recombinant forms of BNP protein. Preferred recombinant polypeptides of the invention are encoded by nucleic acids having at least 85% sequence identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%) with the nucleic acid sequence of NCBI gene ID: 4879 in addition to the native BNP protein. In preferred embodiments, the variant BNP protein has one or more functional activities of the native BNP protein.

[0049] In various embodiments, the modified BNP is full-length BNP. In other embodiments, the modified BNP is truncated at the C-terminus and / or N-terminus of SEQ ID NO:1. As shown in FIG. 1, BNP contains a disulfide bridge between Cys10 and Cys26. BNP can be truncated toward the disulfide bridge from either the C-terminus or the N-terminus, or both, without substantial loss of activity. See, for example, Example 4, in which PASylated BNP1-30, PASylated BNP3-32, and PASylated BNP6-32 performed comparably to PASylated BNP1-32 in the hNPR1 agonism assay.

[0050] Modified BNP can also include one or more additional proteins, either recombinantly or chemically covalently or non-covalently bound thereto, such as one or more additional modified or unmodified BNP, a protein containing an antibody binding site, a urocortin such as stresscopin, or any other bioactive protein.

[0051] Thus, the truncated BNPs are: BNP2-32, BNP3-32, BNP4-32, BNP5-32, BNP6-32, BNP7-32, BNP8-32, BNP9-32, BNP10-32, BNP1-31, BNP2-31, BNP3-31, BNP4-31, BNP5-31, BNP6-31, BNP7-31, BNP8-31, BNP9-31, BNP10-31, BNP1-30, BNP2-30, BNP3-30, BNP4-30, BNP5-30, BNP6-30, BNP7-30, BNP8-30, BNP9-30, BNP10-30, BNP1-29, BNP2-29, BNP3-29, BNP4-29, BNP 5-29, BNP6-29, BNP7-29, BNP8-29, BNP9-29, BNP10-29, BNP1-28, BNP2-28, BNP3-28, B NP4-28, BNP5-28, BNP6-28, BNP7-28, BNP8-28, BNP9-28, BNP10-28, BNP1-27, BNP2-27, It may be BNP3-27, BNP4-27, BNP5-27, BNP6-27, BNP7-27, BNP8-27, BNP9-27, BNP10-27, BNP1-26, BNP2-26, BNP3-26, BNP4-26, BNP5-26, BNP6-26, BNP7-26, BNP8-26, or BNP9-26.

[0052] The polymers of these embodiments may be of various lengths and molecular weights. In some embodiments, the polypeptide forms a random coil structure. The polymers can have any length. In some embodiments, the length of the polymer is less than 200 amino acids. In other embodiments, the length of the polymer is between 200 and 1000 amino acids, including multiples of 200. Each 200 amino acid biopolymer unit confers a calculated molecular weight of about 17 kDa to the molecule to which it is attached. The use of modified amino acids or amino acid mimetics in these polymers is also contemplated.

[0053] The polymers of some of these modified BNP embodiments include an amino acid sequence (PAS) consisting of proline and alanine residues, and optionally serine residues.

[0054] In some embodiments, the polymer comprises any one or any combination of the following amino acid sequences: ASPAAPAPASPAAPAPSAPA (SEQ ID NO: 2), AAPASPAPAAPSAPAPAAPS (SEQ ID NO: 3), APSSPSPSAPSSPSPASPSS (SEQ ID NO: 4), SAPSSPSPSAPSSPSPASPS (SEQ ID NO: 5), SSPSAPSPSSPASPSPSSPA (SEQ ID NO: 6), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO: 7), ASAAAPAAASAAASAPSAAA (SEQ ID NO: 8), APAAPAPAPAAPAPAPA (SEQ ID NO: 9), AAPAPAPAAPAPAPAAP (SEQ ID NO: 10), APPPAPPPAP (SEQ ID NO: 11), PAPPPAPPPA (SEQ ID NO: 12), AAPAAPAPPAAAPAAPAPPA (SEQ ID NO: 13) and AAAAPAAAAAAAPAAA (SEQ ID NO: 14) or permuted or circularly permuted versions or multimers of these sequences as a whole or as part of these sequences.

[0055] In some cases, terminating the polymer with proline has been found to aid in the subsequent purification of the modified BNP. Thus, in various embodiments, the polymer is terminated with proline.

[0056] Particularly useful polymers include SEQ ID NO:2 repeated at least 10 times, at least 20 times, at least 30 times, at least 40 times, or more, and optionally terminated with a proline. In some of these embodiments, the polymer is attached to BNP at the extra alanine of the polymer. In other embodiments, an extra alanine is used to terminate the polymer sequence.

[0057] The PAS polymer(s) of the modified BNP can be covalently attached to either or both of the N-terminus or C-terminus of BNP. Additionally or alternatively, the polymer(s) can be attached to any amino acid side chain residue of BNP outside of the disulfide bridge, i.e., any of residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 27, 28, 29, 30, 31, or 32 of SEQ ID NO:1.

[0058] In some embodiments, the modified BNP comprises a cysteine ​​inserted or substituted between any of residues 1-9 or 27-32 of SEQ ID NO:1. In these embodiments, the cysteine ​​further comprises a polymer. See Example 1. Figure 4 shows a non-limiting example of a modified BNP in which a cysteine ​​replaces a native amino acid in BNP and a PAS polymer is attached to the non-native cysteine. The amino acid polymer may be attached to the free cysteine ​​in the BNP derivative using any of a variety of linkers known in the art, including a methylcarbonyl group (IA) derived from activated iodoacetic acid (IA in Figure 4).

[0059] To facilitate the conjugation of the amino acid polymer to BNP, a linker between BNP and the polymer can be utilized. Any linker known in the art that can facilitate this conjugation can be utilized. Examples are provided in US Patent Application Publication No. 2011 / 0105397, e.g., paragraph 135, and references cited therein. In some embodiments, the linker moiety is N-(ethylcarbonyl)succinimide or methylcarbonyl. These linkers have the following structure: [ka]

[0060] The modified BNPs described herein can include any number of polymers, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 polymers. When there is more than one polymer on the modified BNP, the polymers can be the same or different in composition and / or length.

[0061] In some embodiments, the polymer is at the N-terminus or C-terminus of BNP. Such terminal polymers may be produced genetically, for example, by encoding the polymer with BNP in a DNA sequence and expressing the sequence. Thus, nucleic acid molecules encoding modified BNPs having amino acid polymers at either or both the N-terminus and / or C-terminus are also provided herein, as are vectors containing the nucleic acid molecules. Also provided herein are cells containing the vectors, including cells capable of expressing the modified BNPs.

[0062] Specific modified BNPs provided herein include, but are not limited to, P-(SEQ ID NO:2) 10 -A-hBNP(1-32) (PAS attached to the N-terminal amino group) (Compound 1 in the Examples below), P- (SEQ ID NO:2) 10 -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3) (Compound 2 in the Examples below), P- (SEQ ID NO:2) 10 -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6) (Compound 3 in the following example), hBNP(1-32)- (SEQ ID NO: 2) 10 -A (PAS bound to the C-terminal carboxy group) (Compound 4 in the following Examples), hBNP(1-30)- (SEQ ID NO: 2) 10 -A (PAS attached to the carboxy group of the C-terminal arginine 30) (Compound 5 in the Examples below), P- (SEQ ID NO: 2) 20 -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO: 2) 20 -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO: 2) 20-A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) 20 -A (PAS bound to the C-terminal carboxyl group), hBNP(1-30)- (SEQ ID NO: 2) 20 -A (PAS bound to the carboxy group of the C-terminal arginine 30), P- (SEQ ID NO: 2) 30 -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO: 2) 30 -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO: 2) 30 -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) 30 -A (PAS bound to the C-terminal carboxyl group), hBNP(1-30)- (SEQ ID NO: 2) 30 -A (PAS bound to the carboxy group of the C-terminal arginine 30), P- (SEQ ID NO: 2) 40 -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO: 2) 40 -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO: 2) 40 -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) 40 -A (PAS attached to the C-terminal carboxy group), or hBNP(1-30)- (SEQ ID NO: 2) 40 -A (PAS bound to the carboxy group of the C-terminal arginine 30).

[0063] In some embodiments, modified BNP is produced in the cells. For example, host cells transfected with a nucleic acid vector directing the expression of a nucleotide sequence encoding a polypeptide of interest can be cultured under appropriate conditions to allow expression of the peptide to occur. The cells can be harvested, lysed, and the protein isolated. Recombinant BNP protein can be isolated from the host cells using techniques known in the art for purifying proteins, including ion exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such proteins.

[0064] Pharmaceutical Preparations and Methods of Administration In some embodiments, the modified BNP described above is formulated in a pharma- ceutically acceptable carrier.These compositions can be administered to subjects in a therapeutically effective dose to treat any disease, disorder, or medical condition mediated by NPR1 activity.Subjects can be any mammal, reptile, or bird, including horses, cows, dogs, cats, sheep, pigs, and chickens, and humans.

[0065] Therapeutically Effective Dose The toxicity and therapeutic efficacy of such compositions are determined by the LD 50 (lethal dose for 50% of the population) and ED 50 The dose that is therapeutically effective in 50% of the population can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effects is called the LD 50 / ED 50 The therapeutic index can be expressed as a ratio of . Compositions that exhibit a high therapeutic index are preferred. Compositions that exhibit toxic side effects may be used, but care must be taken to design a delivery system that targets such compositions to the site affected by the disease or disorder in order to minimize potential damage to non-affected cells and reduce side effects.

[0066] The data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans and other mammals. The dosages of such compositions are preferably administered at doses that are within the ED range with little or no toxicity. 50 The therapeutically effective dose for any composition of the invention can be estimated initially from cell culture assays. The dose is determined based on the EC 50 The composition may be formulated in animal models to achieve a circulating plasma concentration range that includes (the concentration of the test composition that achieves half-maximal effect). Such information can be used to more accurately determine useful dosages in humans and other mammals. Levels of the composition in plasma can be measured, for example, by high performance liquid chromatography.

[0067] The amount of the composition that can be combined with a pharma- ceutically acceptable carrier to produce a single dosage form varies depending on the host being treated and the particular method of administration. Those skilled in the art will understand that the unit content of the composition contained in each individual dose of each dosage form does not necessarily constitute a therapeutically effective amount in itself, and the required therapeutically effective amount can be reached by administering several individual doses. The choice of dosage depends on the dosage form being utilized, the condition being treated, and the particular purpose to be achieved according to the determination of those skilled in the art.

[0068] Dosage regimens for treating a disease or condition with compositions and / or combinations of compositions of the present invention are selected according to a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicological profile of the particular composition employed, whether a composition delivery system is utilized, and whether the composition is administered as part of a prodrug or drug combination. Thus, the actual dosing regimen employed may vary widely between subjects.

[0069] Formulation and Use The compositions of the present invention can be formulated by known methods for administration to a subject using several routes, including, but not limited to, parenteral, oral, topical, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, inhalation, and intraocular routes. Individual compositions may also be administered in combination with one or more additional compositions of the present invention and / or with other biologically active or biologically inactive agents ("combination of compositions"). Such biologically active or inactive agents may be in fluid or mechanical communication with the composition, or may be bound to the composition by ionic, covalent, van der Waals, hydrophobic, hydrophilic, or other physical forces. Administration is preferably localized in the subject, but administration may also be systemic.

[0070] The composition or the combination of compositions may be formulated by any conventional method using one or more pharma- ceutically acceptable carriers and / or excipients. Thus, the compositions and their pharma- ceutically acceptable salts and solvates may be formulated for administration parenterally, by inhalation or insufflation (either by mouth or nose), or by oral, buccal, parenteral, or rectal administration. The composition or the combination of compositions may take the form of a charged salt, a neutral salt, and / or other pharma- ceutically acceptable salt. Examples of pharma-ceutically acceptable carriers include, but are not limited to, those described in Remington's Pharmaceutical Sciences (AR Gennaro, Ed.), 20th edition, Williams & Wilkins PA, USA (2000).

[0071] The compositions can take the form of a solution, suspension, emulsion, tablet, pill, capsule, powder, controlled release or sustained release formulation, etc. Such compositions will contain a therapeutically effective amount of the composition, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should be compatible with the mode of administration.

[0072] Parenteral Administration The composition or the combination of compositions can be formulated for parenteral administration by injection, for example, bolus injection or continuous infusion. The formulation for injection can be provided in unit dosage form, for example, in ampoules or in multi-dose containers, with optional preservatives added. Parenteral preparations can be enclosed in ampoules, disposable syringes, or multi-dose vials, such as made of glass or plastic. The composition can take the form of a suspension, solution, or emulsion in an oily or aqueous vehicle, and can contain formulating agents, such as suspending, stabilizing, and / or dispersing agents.

[0073] For example, parenteral preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents (e.g., solutions in 1,3-butanediol). Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any smooth fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used in parenteral preparations.

[0074] Alternatively, the composition may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. For example, a composition suitable for parenteral administration may contain sterile isotonic saline containing 0.1% to 90% by weight per volume of the composition or combination of compositions. By way of example, a solution may contain about 5% to about 20% of the composition, more preferably about 5% to about 17%, more preferably about 8 to about 14%, and even more preferably about 10%. The solution or powder preparation may also contain a solubilizing agent and a local anesthetic, such as lidocaine, to ease pain at the site of injection. Other methods of parenteral delivery of the composition are known to those skilled in the art and are within the scope of the present invention.

[0075] Other delivery systems A variety of other delivery systems are known in the art and can be used to administer the compositions of the present invention. Additionally, these and other delivery systems can be combined and / or modified to optimize administration of the compositions of the present invention. In some embodiments, the formulations can be aerosolized.

[0076] Active Ingredient Kit In various embodiments, the present invention can also include a kit. Such a kit can include the composition of the present invention and, in certain embodiments, instructions for administration. When supplied as a kit, the different components of the composition can be packaged in separate containers and mixed immediately before use. Such packaging of the components can be presented in a pack or dispenser device that can contain one or more unit dosage forms containing the composition, if desired. The pack can include, for example, a metal or plastic foil, such as a blister pack. Such packaging of the components can also allow for long-term storage without losing activity of the components in certain cases. Furthermore, if more than one route of administration is intended, or if more than one administration schedule is intended, the different components can be packaged separately and not mixed before use. In various embodiments, the different components can be packaged in one composition for administration together.

[0077] The kit may also include reagents in separate containers, such as, for example, sterile water or saline, which is added to the separately packaged lyophilized active ingredient. For example, a sealed glass ampoule may contain lyophilized phosphatase, with separate ampoules, sterile water, sterile saline, or each sterile ampoule packaged under a neutral non-reactive gas, such as nitrogen. The ampoules can be made of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, ceramic, metal, or any other material typically used to hold reagents. Other examples of suitable containers include bottles, which may be made from similar materials as the ampoules, and envelopes, which may be made of a foil-lined interior, such as aluminum or alloy. Other containers include test tubes, vials, flasks, bottles, syringes, and the like. The container may have a sterile access port, such as a bottle with a stopper that can be pierced by a hypodermic needle. Other containers may have two compartments separated by an easily removable membrane that allows the components to mix upon removal. The removable membrane may be glass, plastic, rubber, and the like.

[0078] In certain embodiments, the kit can be supplied with instructions. The instructions can be printed on paper or other substrate and / or can be supplied as an electronically readable medium, such as a thumb drive, CD-ROM, DVD-ROM, video, audio, etc. The detailed instructions may not be physically associated with the kit, but instead the user may be directed to an internet website designated by the kit manufacturer or distributor.

[0079] Treatment method Also provided is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant, including a fibrotic or inflammatory disease, comprising administering to a subject in need of such treatment a therapeutically effective amount of any of the modified BNPs described above.

[0080] In some embodiments, the disease, disorder, or medical condition is a hematological disease, a neurological disease, a developmental disease, a urological disease, a reproductive disorder, a psychiatric disorder, a cancer, an autoimmune disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an infectious disease, a pulmonary disease, a cardiac disease, a vascular disease, or a metabolic disease.

[0081] In some of these embodiments, the disease, disorder, or medical condition is anxiety, depression, post-traumatic stress disorder, obesity, peripherally acting inflammatory bowel disease, irritable bowel syndrome, stress response, sleep disorders, addictive behaviors, acute and chronic neurodegeneration, premature birth or pain, vasculitis and / or excessive angiogenesis in autoimmune disorders, systemic sclerosis, multiple sclerosis, Sjogren's disease, vascular and / or lymphatic malformations, left ventricular hypertrophy, portal hypertension, hepatic ascites, pulmonary hypertension, idiopathic pulmonary hypertension, atrial hypertension, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary fibrosis, DiGeorge syndrome, hereditary hemorrhagic telangiectasia, cavernous hemangiomas, cutaneous hemangiomas, lymphatic malformations, implantable adenomas, atherosclerosis. , vascular anastomoses, adipose tissue in obesity, allograft rejection, skin diseases, psoriasis, warts, allergic dermatitis, scar keloids, pyogenic granulomas, bullous diseases, Kaposi's sarcoma in AIDS patients, systemic sclerosis, eye diseases, persistent hyperplastic vitreous syndrome, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, pulmonary hypertension, asthma, nasal polyps, rhinitis, chronic airway inflammation and obstruction, cystic fibrosis, acute lung injury, bronchiolitis obliterans organizing pneumonia, gastrointestinal diseases, inflammatory bowel diseases, periodontal diseases, ascites, peritoneal adhesions, liver cirrhosis, reproductive system diseases, endometriosis, uterine bleeding, ovarian cysts, ovarian hyperstimulation, bone or joint diseases, arthritis, synovitis, osteomyelitis, osteophyte formation, HIV-induced bone marrow angiogenesis, kidney diseases, or early diabetic nephropathy.

[0082] As mentioned above, the compositions can be administered by any suitable method known in the art. In some embodiments, administration is by injection. In other embodiments, the modified BNP is aerosolized and administered by inhalation.

[0083] Method of preparation The above-mentioned composition can be prepared by any suitable method known in the art.When the polymer is at the N-terminus or C-terminus of BNP, the above-mentioned cell containing the vector encoding modified BNP can express modified BNP.When the polymer is conjugated to one or more amino acid residues of BNP, modified BNP can be produced by solution or solid-phase techniques, and then the polymer can be covalently attached using chemical methods.Such techniques and methods are well known in the art.

[0084] Preferred embodiments are described in the following examples. Other embodiments within the scope of the claims will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

[0085] Usefulness of PAS-type ANP and urodilatin The compositions and methods provided herein can be applied to ANP and urodilatin to produce PASylated ANP and urodilatin that retain the biological activity of native ANP and urodilatin. EXAMPLES

[0086] Example 1 - Synthesis of BNP Derivatives The BNP1-32 derivatives were obtained by solid-phase or solution-phase chemistry, or a mixture of both. As a result of having two cysteines in the molecule required to form disulfide bridges, as well as others to bind the PAS moiety, an orthogonal protecting group strategy was used. Other chemical synthesis techniques may be used to achieve the orthogonal protecting group strategy.

[0087] The PAS group itself is prepared by recombinant means. The recombinant product is isolated before being derivatized at its N-terminus, usually an alanine residue, with a linking reagent capable of reacting with the free cysteine ​​thiol in the BNP derivative. The linkers used are methylcarbonyl (IA in FIG. 4) or N-(ethylcarbonyl) succinimide. When IA is used as a linker reagent consisting of the appropriate sequence of proline and alanine or proline, alanine and serine, H2OC-(Pro / Ala)-Ala-NHCOCH2I or H2OC-(Pro / Ala / Ser)-Ala-NHCOCH2I are prepared from PAS by reacting with carboxy-activated iodoacetic acid. These PASylating reagents are then reacted with the free cysteine ​​thiol in the BNP derivative to obtain the PASylated peptide. For example, residue 1 may be mutated from S to C, residue 3 may be mutated from K to C, residue 4 may be mutated from M to C, residue 5 may be mutated from V to C, residue 6 may be mutated from Q to C, and residue 8 may be mutated from S to C.

[0088] PASylation (A) results in delayed renal filtration of BNP, while (B) confirms whether any side chains at the N-terminus are non-essential for conferring receptor affinity to the hormone, and (C) inhibits proteolytic enzymatic cleavage that would facilitate extended half-life.

[0089] Those skilled in the art will recognize that other methods of PASylating the BNP protein are available, including via chemistry to modify the C-terminus of the BNP protein, or by heterologous gene expression of BNP genetically fused to a PAS sequence or polymer at either the N-terminus or C-terminus.

[0090] Example 2 - PASification of BNP Synthetic DNA fragments encoding amino acids 1-32 (compounds 1 and 4), 3-32 (compound 2), 6-32 (compound 3) or 1-30 (compound 5) of human BNP were obtained from Thermo Fisher Scientific (Regensburg, Germany). The gene fragments of compounds 1-3 (SEQ ID NOs: 21, 22, 23) contain an NdeI restriction site followed by a CCT proline codon, a GCC alanine codon, a first SapI recognition sequence GCTCTTC on the non-coding strand, an 8 nucleotide spacer, and a second SapI restriction sequence in the reverse orientation, and on the coding strand contains its recognition sequence GCTCTTC, followed by a GCC alanine codon and the coding sequence for human BNP (or a fragment thereof), finally followed by a HindIII restriction site. The order of coding elements on the gene fragments of compounds 4 and 5 (SEQ ID NOs: 24, 25) was as follows: an NdeI restriction site, a coding sequence for human BNP (or a fragment thereof), a GCC alanine codon, a first SapI recognition sequence GCTCTTC on the non-coding strand, an 8 nucleotide spacer, and a second SapI restriction sequence in the reverse orientation to its recognition sequence GCTCTTC on the coding strand, followed by a GCC alanine codon and a TAA stop codon.

[0091] To clone the BNP DNA constructs on the expression plasmid pD451-SR (ATUM, Newark, Calif.), the original SapI cloning site on the vector was replaced with a sequence containing NdeI and HindIII recognition sites. To this end, the vector was digested with XbaI and StyI, and the backbone was religated with a double-stranded pair of synthetic oligonucleotides containing a ribosome binding site (RBS), an NdeI site, a HindIII site, and flanking cohesive ends compatible with the XbaI and StyI sites.

[0092] The BNP gene fragment was then inserted into a modified pD451-SR vector via the restriction sites NdeI and HindIII according to standard procedures (Sambrook (2012) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press). Each resulting plasmid was then digested with SapI, thereby liberating a small (27 bp) DNA insert containing a pair of SapI recognition sites as part of the synthetic DNA fragment described above, and a vector backbone with compatible 5'-GCC / 5'-GGC sticky ends located either immediately upstream of the encoded N-terminus of BNP (compounds 1-3) or immediately downstream of the C-terminus (compounds 4 and 5). This strategy is ideally suited for the insertion of low-repeat nucleic acid molecules encoding proline / alanine-rich amino acid repeat sequences. The vector fragment was isolated using the Wizard gel extraction kit (Promega, Mannheim, Germany) and dephosphorylated with the heat-sensitive alkaline phosphatase FastAP (Thermo Fisher Scientific, Waltham, Mass.) before being ligated with a previously cloned PAS#1.2(200) gene cassette (SEQ ID NO:26) carrying compatible overhangs as described (WO2017 / 109087A1). The resulting plasmid allows the bacterial expression of an in-frame fusion protein containing the PAS sequence fused at either the N- or C-terminus with a biologically active BNP peptide (or a fragment thereof).

[0093] E. coli T7 expression competent cells (New England Biolabs, Ipswich, MA) were transformed with one of the following expression plasmids: pD451-SR-PAS200-BNP32 (SEQ ID NO: 27) for compound 1, pD451-SR-PAS200-BNP(3-32) (SEQ ID NO: 28) for compound 2, pD451-SR-PAS200-BNP(6-32) (SEQ ID NO: 29) for compound 3, pD451-SR-BNP32-PAS200 (SEQ ID NO: 30) for compound 4, and pD451-SR-BNP(1-30)-PAS200) (SEQ ID NO: 31) for compound 5. Erlenmeyer flasks containing 50 mL of TB medium (Carl Roth, Karlruhe, Germany) supplemented with kanamycin (30 mg / l) were inoculated with a single colony for each of the transformations and incubated at 37° C. overnight. 10 ml of this preculture was used to inoculate a shake flask containing 2 L of TB medium (containing 30 mg / l kanamycin). The mixture was incubated at 30° C. for 16 hours and incubated until an optical density (OD ) of approximately 3 was reached. 600 After reaching a pH of 10, recombinant gene expression was induced by adding 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to the culture. E. coli cells were harvested 4 h after induction by centrifugation (6,000 rpm, 25 min, 4°C) and cell pellets (approximately 10 g per shake flask) were frozen at -20°C.

[0094] Cell lysis was performed after resuspension of the pellet in 100 mM Tris / HCl (pH 8.5) (4.4 volumes) by adding 0.15% (v / v) tergitol 15-S-9 type (Sigma-Aldrich, St. Louis, MO), egg white lysozyme (4 mg per 10 g pellet; Sigma-Aldrich), cyanase nuclease (250 U per 10 g pellet; SERVA Electrophoresis, Heidelberg, Germany) and 40 μM MgCl2. After incubation of the lysis mixture on ice for 2 h, the soluble fraction was separated from the cell debris by centrifugation (39,000 × g, 1.5 h, 4 °C). The clarified supernatant was subjected to ammonium sulfate precipitation (30% saturation at room temperature) and the precipitate was solubilized in 25 mM Na-borate buffer (pH 9.5) supplemented with 1 mM EDTA. Residual ammonium sulfate was removed by dialysis against borate buffer.

[0095] The resulting protein extract was subjected to subtractive anion exchange chromatography on a Fractogel EMD TMAE(S) column (Merck, Darmstadt, Germany) followed by Fractogel EMD SO3 - The fusion protein was subjected to cation exchange chromatography (binding mode) on a (S) column (Merck). The PAS200-BNP fusion protein was eluted from this column by applying a 0-500 mM NaCl gradient in borate buffer (see above). Eluate fractions were analyzed by SDS-PAGE, pooled as required, and dialyzed against ultrapure water. Salt-free PAS200-BNP32 was lyophilized to give a yield of 5-10 mg per 2 L shake flask culture, as determined gravimetrically.

[0096] ESI-MS analysis of purified compound 1 (Figure 15B) revealed a single mass peak corresponding to the expected mass of PAS200-BNP32 with a correctly formed intramolecular disulfide bridge (20150.7 Da) and also indicated a cleaved initiating -Met. The mass spectrum did not reveal any hints of a potentially disulfide-linked PAS200-BNP dimer or any indication of proteolysis. Analytical size-exclusion chromatography (SEC) on a Superose 6, 10 / 300 column (Cytiva, Uppsala, Sweden) with phosphate-buffered saline (PBS) as running buffer eluted PASylated BNP as a monodisperse macromolecule in a single peak in a volume of 16.5 ml (Figure 15A), indicating a uniform polypeptide preparation. Calibration of the column with globular proteins of known molecular weight allowed the determination of an apparent molecular weight of 93 kDa for PASylated BNP. This increased apparent molecular weight is due to the random coil nature of the PAS moiety, which results in a strongly increased hydrodynamic volume.

[0097] Example 3 - Administration of BNP Test Purpose This study determines that chronic (3 months) treatment with BNP protein with induced random coiling in dogs with ischemia-induced, progressive, irreversible heart failure is associated with: (1) preservation and / or improvement of LV structure and function, (2) no change or long-term reduction in biomarkers of myocardial damage, and (3) no significant de novo ventricular arrhythmias or increased susceptibility to malignant arrhythmias compared to placebo (vehicle). See also Example 6.

[0098] Testing Protocol This study analyzed 24 dogs with advanced heart failure (HF) caused by multiple consecutive intracoronary microemboli (LV ejection fraction ≦25%) (1). Dogs are randomized into three study groups. Group I (n=8) receives subcutaneous vehicle injections for 3 months while serving as a placebo control. Group II (n=8) receives chronic treatment with a BNP derivative (0.1 mg / kg, Q5d) for 3 months. Group III (n=8) receives chronic treatment with a BNP derivative (0.3 mg / kg, Q5d) for 3 months. All administrations are performed at the same time of day in a 20 cm x 24 cm area. Within a shaved 20 cm x 24 cm area in the anterior scapular region (scruff) of the animal's neck, six (6) areas are outlined with the centers of each area 12 cm apart. The regions are numbered as outlines, and the order of injections is region 1, 5, 3, 6, 2, 4. Hemodynamic, angiographic and echocardiographic measurements are performed during left and right cardiac catheterization under general anesthesia. Left and right cardiac catheterizations are performed at baseline, 7 days prior to placebo vehicle or BNP derivative injection, 24 hours after the first BNP derivative injection, 24 hours after the third BNP derivative injection (day 10), 24 hours after the fifth BNP derivative injection (day 20), 24 hours after the seventh BNP derivative injection (day 30), 24 hours after the twelfth BNP derivative injection (day 60), and 24 hours after the eighteenth BNP derivative injection (day 90). Following hemodynamic and ventriculographic measurements on day 90, the chest is rapidly opened and a 0.5-1.0 g portion of the left ventricle is rapidly removed and snap frozen in a Wollenberger clamp cooled in liquid nitrogen for myocardial cyclic guanosine monophosphate (cGMP) analysis. Levels of cGMP in plasma are also analyzed. Samples are then removed for histotype measurements, myocardial receptor and ion channel measurements, and RNA gene chip analysis. Venous blood samples are obtained at the same time of day in conscious dogs prior to each cardiac catheterization and echocardiography measurement, including days -7, 0-16, 22, 30, 38, 45, 53, 60, 68, 75, 83, and 90.Blood samples (at least 9 mL - 3 x 3 ml) are collected in plastic tubes containing EDTA and complete protease inhibitors (Roche Biosciences). Each EDTA blood collection tube contains 40 μL complete protease inhibitor per ml of whole blood from a stock solution of one complete protease inhibitor tablet of the following composition dissolved in 2 ml of saline. Whole blood samples are collected with EDTA and protease inhibitors. Whole blood samples collected with EDTA and protease inhibitors are immediately placed on ice and centrifuged at 3000 rpm for 10 minutes within 30 minutes of collection. Plasma is (i) placed in cryopreservation tubes and (ii) stored upright at -70°C until analysis to determine LANA plasma concentrations. Samples of dosing solution (2 mL) are placed in cryopreservation tubes and stored upright at -70°C. Separate venous blood samples (serum) are collected at baseline and at the end of each cardiac catheterization for determination of serum electrolytes, including creatinine to estimate eGFR. For plasma biomarkers, venous blood is collected at baseline and at the end of each cardiac catheterization. Dogs' body weights are measured monthly, immediately prior to each cardiac catheterization.

[0099] Hemodynamic and angiographic measurements All hemodynamic measurements are performed by left and right cardiac catheterization in anesthetized dogs at each designated study time point. The following parameters are assessed in all dogs: (1) aortic and LV pressures using a catheter tip micromanometer (Millar Instruments), (2) peak rate of change of LV pressure during isoboromic contraction (peak + dP / dt) and relaxation (peak - dP / dt), (3) LV end-diastolic pressure, (4) cardiac output, (5) stroke ejection, (6) cardiac index, and (7) total peripheral resistance.

[0100] Left ventriculography (LV) is performed on dogs during cardiac catheterization after completion of hemodynamic measurements. Dogs are positioned on their right side so that LV ventriculograms are recorded on digital media at 30 frames / s during power injection of 20 mL of contrast material (RENO M60, Squibb Diagnostics). Correction for image magnification is performed using a radiopaque grid placed at the level of the LV. LV end-systolic and end-diastolic volumes are calculated from the angiographic silhouettes using the area-length method. Premature and post-systolic beats are excluded from the analysis. LV ejection fraction is calculated as the ratio of the difference between end-diastolic (EDI) volume and end-systolic (ESY) volume to end-diastolic volume × 100. LV ejection fraction = [(volume EDI-volume ESY) / volume ED] x 100

[0101] Echocardiogram and Doppler measurements Echocardiographic and Doppler studies will be performed in all dogs at designated study time points using a Vivid 7 ultrasound system (General Electric) equipped with a 3.5 megahertz (MHz) transducer. All echocardiographic measurements will be performed with the dog in the right lateral decubitus position and recorded on a Panasonic 6300 VHS recorder for subsequent off-line analysis.

[0102] LV fractional area contraction (FAS) and LV systolic function are measured from the short axis view at the level of the papillary muscles. LV major and minor radii are measured and used to calculate LV end-diastolic circumferential wall stress.

[0103] The wall stress is calculated as shown below. Wall stress=Pb / h(1-h / 2b)(1-hb / 2a2) where P is the LV end-diastolic pressure, a is the LV long axis, b is the LV short axis, and h is the LV wall thickness.

[0104] Circumferential global strain (GLS) is measured by speckle tracking.

[0105] Mitral inflow velocity is measured by pulsed wave Doppler echocardiography to assess LV diastolic function. The velocity waveform is used to calculate: (i) peak mitral flow velocity in early diastole (PE), (ii) peak mitral inflow velocity during LA contraction (PA), (iii) the ratio of PE to PA (PE / PA), (iv) the time velocity integral (Ei) of the mitral inflow velocity waveform representing early inflow, (v) the time velocity integral (Ai) representing LA contraction, (vi) the ratio of Ei / Ai (Ei / Ai), and (vii) the deceleration time of early mitral inflow velocity (DT). Color flow Doppler assesses the presence and severity of functional mitral regurgitation (i.e., regurgitant jet). The severity of regurgitation, if present, is quantified as the ratio of the area of ​​the regurgitant jet to the area of ​​the left atrium.

[0106] Twenty-four-hour ambulatory Holter electrocardiogram monitoring performed at all prespecified time points (baseline, 1, 2, 14, 30, 60, and 90 days) will include: (1) peak, (2) mean and minimum heart rates, and (3a) mean number of single premature beats (PVCs) per hour, (3b) couplets, (3c) triplets, and (3c) episodes of ventricular tachycardia (VT) (>3 beats). Episodes of nonsustained VT are defined as those lasting less than 30 seconds. Episodes lasting more than 30 seconds are defined as "sustained VT."

[0107] Circulating Plasma Biomarkers Venous blood samples were obtained at baseline and each follow-up time point (baseline and after each cardiac catheterization) to quantify the following plasma biomarkers: (1) troponin-I, (2) myoglobin, (3) big endothelin (Big-ET), (4) angiotensin-II (ANGII), (5) norepinephrine (NE), (6) N-terminal pro-BNP (NT-proBNP), (7) atrial natriuretic peptide (proANP), (8) tumor necrosis factor alpha (TNF-alpha), (9) interleukin-6 (IL-6), (10) C-reactive protein (CRP), (11) C-terminal propeptide of procollagen type 1 (PICP), (12) CK-MB, and (13) cyclic guanosine monophosphate (cGMP). Blood samples from six normal dogs were compared.

number

[0108] Histomorphometric measurements Three transverse slices (approximately 3 mm thick) are obtained from each heart, one from each of the base, mid, and apical thirds of the LV. From each slice, a transmural tissue block is obtained and embedded in a paraffin block. Transmural tissue blocks obtained from the free wall segments of the slices are (i) fixed on a cork using Tissue-Tek embedding medium, (ii) rapidly frozen in isopentane pre-cooled in liquid nitrogen, and (iii) stored at -70°C until used. Volume fraction of replacement fibrosis (VFRF), volume fraction of interstitial fibrosis (VFIF), myocyte cross-sectional area (MCSA), a measure of cardiomyocyte hypertrophy, capillary density (CD), and oxygen diffusion distance (ODD) are measured as previously described. LV tissue from six normal dogs is processed in the same manner as above, and the results are used for comparison.

[0109] Measurement of myocardial receptors and ion channels From each heart, approximately 1-5 g of LV anterior free wall is rapidly removed, dissected, and snap frozen at -80 °C for radioligand binding. The density and affinity of beta-adrenergic receptors and cardiac sarcoplasmic reticulum calcium release channels are determined by [3 H]-dihydroalprenolol and [ 3 H]-ryanodine is quantified by analyzing the saturation isotherm from specific binding to abundant sarcolemmal and cardiac sarcoplasmic reticulum membranes.

[0110] RNA gene chip analysis The RNA gene chip analysis used with the compositions and methods herein includes expression profiling, samples taken, treatment groups, and tissues. Thus, there are two samples per hound (one for RNA and one for protein), with the tissues later stored for RNA and half kept at -70°C for protein.

number

[0111] Methods for collection The sections were 5 mm 3 After dissection, the tissues are rinsed in RNALater and stored in 1 mL of RNALater, then stored in labeled 1.5 mL polypropylene Eppendorf tubes. Vascular tissue (artery or vein) is collected as 1 cm lengths.

[0112]

[0151] In analyzing the above data, the results are compared to data obtained from administration of native BNP and PEGylated BNP. The half-life of the BNP protein is expected to be increased without the undesirable immunogenic properties produced by PEGylation.

[0113] Overview of Examples 4 and 5 Examples 4 and 5 describe studies evaluating the biological activity of five PASylated forms of BNP: PASylated compounds 1-5 were prepared by recombinant means well known to those of skill in the art and are shown in Figure 5. Compound 1 is P-(SEQ ID NO:2) 10 -A-hBNP(1-32) (PAS attached to the N-terminal amino group). Compound 2 is P-(SEQ ID NO:2) 10-A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3). Compound 3 is P-(SEQ ID NO:2) 10 -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6). Compound 4 is hBNP(1-32)-(SEQ ID NO:2) 10 -A (PAS attached to the C-terminal carboxy group). Compound 5 is hBNP(1-30)-(SEQ ID NO:2) 10 -A (PAS bound to the carboxy group of the C-terminal arginine 30).

[0114] Example 4. NPR1 agonist activity of PAS-type BNP The aim of this study is to evaluate the potential functional effects of test compounds on hNPR1 (the membrane-bound guanylate cyclase receptor for BNP) under agonist mode by detection of cGMP levels by TR-FRET.

number

number

number

[0115] Experimental procedure Transient transfection One day prior to transfection, cells were harvested and counted for density and viability using a Countess cell counter. Only cells with viability >85% were used for the following assays. Cells were seeded at a density of 9.75 x 105 cells / dish in 6 cm dishes and cultured overnight at 37°C, 5% (v / v) CO2. The following day, growth medium was discarded and 3 ml of Opti-MEM I reduced serum medium was added to each well.

[0116] The following DNA / FuGENE6 reagent mixture was prepared:

number

[0117] After 15 min of incubation at room temperature, the mixture was added to the cells and cultured for 6 h at 37°C in a humidified atmosphere containing 5% (v / v) CO2. The medium was then replaced with complete culture medium (F12 medium supplemented with 10% FBS and 100 U / ml Pen-Strep) and cultured at 37°C in a humidified atmosphere containing 5% (v / v) CO2 before use.

[0118] Cell plating Cells were washed once with PBS and the growth medium was discarded 24 hours after transfection. An appropriate amount of TrypLE was then added and incubated with the cells for 5 minutes at 37°C. When the cell morphology became round, the reaction was stopped by adding complete growth medium. The cells were then transferred to a sterile 15 ml centrifuge tube and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in complete growth medium. The cells were counted using a Countess cell counter. Only cells with a viability of more than 85% were used for the following assays. Complete growth medium was used to dilute the cells, which were then transferred to poly-L-lysine coated 384-well plates at a density of 12,000 cells / well. The cells were then cultured overnight at 37°C in a humidified atmosphere containing 5% (v / v) CO2.

[0119] Agonist assay The reference compound human BNP and the test compounds were dissolved in ddH2O to make a stock solution of 100 μM. The growth medium was discarded and the cells were resuspended in 40 μl of HBSS buffer (Ca 2+ and Mg 2+ The plates were washed once with 10 μl of HBSS buffer (containing Ca) supplemented with 0.5 mM IBMX. 2+ and Mg 2+) was added to each well and then incubated at 37°C for 15 minutes. 10 nL of 3-fold serially diluted compounds were transferred from the source plate to the 384-well plate using the Echo 550. For the reference compounds, the top three concentrations were prepared by transferring 300 nL, 100 nL, and 30 nL of the 100 μM stock solution. For the test compounds, the top four concentrations were prepared by transferring 1000 nL, 300 nL, 100 nL, and 30 nL of the 100 μM stock solution. The plate was centrifuged at 1000 rpm for 1 minute and agitated at 600 rpm. The plate was incubated at 37°C for 20 minutes. Each well of the plate was added 5 5 μl / well of cGMP-d2 working solution and 5 μl / well of anti-cGMP-Eu 3+ Cryptate working solution was added, and the plate was then centrifuged at 1000 rpm for 1 minute, agitated at 600 rpm, and then incubated at 25° C. for 1 hour.

[0120] Plates were read on an EnVison microplate reader (λex=320 nm, λem=615 nm and 665 nm) and dose-response curves were constructed plotting % activation versus compound concentration. The curves were used to determine the EC 50 Values ​​were calculated. Results were expressed as % activation using the normalization equation: N=100-100×(U-C2) / (C1-C2), where U is the unknown value, C1 is the mean of the high controls, and C2 is the mean of the low controls. Lower and upper asymptote, midpoint slope and efficacy (EC 50 ) is determined by fitting the percentage of activation as a function of compound concentration to a four-parameter general logistic function using GraphPad Prism™ software.

[0121] result The results are shown in a graph in FIG.

[0122] The results for each PAS-type BNP are also shown in the following table.

number

[0123] Consideration This example establishes that PASylated BNP has agonist activity at human NPR1.

[0124] Example 5. Evaluation of the efficacy of hBNP(1-32) and Compound 1 in carbachol-preconstricted isolated guinea pig tracheal rings method All animals received standard housing and husbandry with water and food ad libitum. Male albino guinea pigs (Dunkin-Hartley; 400-700 g; Envigo, Horst, NL) were sacrificed by CO2 inhalation followed by exsanguination. Tracheas were gently dissected from the surrounding connective tissue, cut into eight intact rings of equal length each containing two to three cricoid cartilages, and placed in 5 mL tissue organ baths containing Krebs-Ringer PSS (2.5 mM CaCl2), kept at 37 °C and constantly bubbled with carbogen (5% CO2 in O2) to maintain a pH of 7.4.

[0125] After slowly adjusting the resting force to 30 mN, tension (mN) was continuously measured via an isometric transducer. Histamine (0.1 nM-0.3 mM) was added cumulatively as a control for guinea pig tracheal reactivity. Before the pharmacological investigation, indomethacin (3 μM) was added to prevent the release and possible interference of prostaglandins. After a 30 min resting period, the segments were contracted with 3 nM of the muscarinic agonist carbachol, resulting in a stable precontraction of approximately 50-75% of the maximal contraction. When the contractile response reached a plateau, relaxation concentration-response curves were obtained in each ring by cumulatively adding hBNP (1-32) or compound 1 at 0.5 log unit dose intervals (0.1 nM-1 μM) for each agonist, randomized by allocation to the organ bath and to the conduct of the experiment. Responses were expressed as the percentage decrease in tension compared to the initial contractile response to carbachol. These experiments were completed with a combination of papaverine (0.1 mM) and sodium nitroprusside (0.1 mM) concentrations to determine maximal relaxation.

[0126] Calculations and Statistics All data are presented as mean ± SEM. Data were fit by nonlinear regression to a three-parameter general logistic to obtain potency (pEC 50 ), midpoint slope and upper asymptote values ​​were calculated. Statistical analysis was performed using unpaired t-tests for comparisons between two groups using GraphPad Prism 8.2.1 software (GraphPad Software Inc., San Diego, CA, USA). A p-value of <0.05 was considered significant.

[0127] Drugs and Sources Stock solutions and dilutions were prepared according to manufacturers' and suppliers' instructions. NaHCO3, CaCl2, and KCl were obtained from VWR (West Chester, PA, USA). Histamine dihydrochloride, carbachol, papaverine, sodium nitroprusside, Krebs-Henseleit PSS buffer, indomethacin, and human brain natriuretic peptide, hBNP(1-32), were purchased from Sigma-Aldrich (St. Louis, MO, USA). All stock solutions were stored at -20°C. Drug dilutions were made fresh from stocks before each experiment in decreasing concentrations of the vehicle (Krebs-Ringer PSS).

[0128] result In guinea pig tracheal segments, 3 nM carbachol induced a stable precontraction with a 4±6% loss of maximum contraction over the experimental time course (FIG. 10). Cumulative administration of hBNP(1-32) and Compound 1 to the superior precontraction induced parallel concentration-dependent relaxations (slope values: 1.3±0.1 and 1.3±0.3, respectively) with similar maximum effects (Emax: 91±4% and 90±3%, respectively). The potency (pEC 50 : 8.00 ± 0.10) is compound 1 (pEC 50 : 6.79 ± 0.05; p < 0.0001), which was 16 times higher (16.3 ± 1.3).

[0129] Consideration This example further establishes that PASylated BNP retains BNP biological activity in physiological tissues.

[0130] Example 6. Single-dose pharmacokinetic / pharmacodynamic study of Compound 1 following subcutaneous and intravenous administration in Beagle dogs The objective of this study was to determine the pharmacokinetic / pharmacodynamic (PKPD) profile of Compound 1 over a 6-day period following a single dose of Compound 1 following subcutaneous and intravenous administration in beagle dogs.

[0131] Study design Compound 1 was dissolved in phosphate buffered saline at a concentration of 0.4 mg / ml for intravenous administration and 1.8 mg / kg for subcutaneous administration. Group 1 received a subcutaneous bolus of phosphate buffered saline at a dose of 0.5 mL / kg. Group 2 received a subcutaneous bolus of 0.9 mg / kg of Compound 1 at a volume of 0.5 mL / kg. Group 3 received an intravenous bolus of 0.2 mg / kg of Compound 1 at a volume of 0.5 mL / kg. There were three male animals in each group.

[0132] Animals were randomized by weight stratification to achieve comparable distribution of body weights between groups after randomization (within ±20% of the mean body weight value, overall individual body weight range 8-13 kg). Absolute dose volumes for individual animals were calculated based on the animal's most recently recorded body weight.

[0133] All animals were surgically implanted with telemetry transmitters to continuously record arterial blood pressure and heart rate during the first 24 h post-dose using the EMKA telemetry system, IOX2 software, and a BP-2010E non-invasive blood pressure (NIBP) monitor. After 24 h post-dose, blood pressure and heart rate were measured by cuff blood pressure at 24-h intervals (days 3-6).

[0134] Blood samples were taken in all three treatment groups at the following time points: pre-dose (-10 min), 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, 72 h, 96 h, 120 h, and 144 h (post-dose). A 0.5 mL sample was taken from each animal at each time point by venipuncture and placed in a potassium (K2) EDTA treated tube, which was capped and gently inverted to ensure anticoagulation. These were stored on ice for up to 60 min, then centrifuged at approximately 2,000 g for 10 min at 4°C to allow removal of the plasma. The plasma was divided into two aliquots (equal volume) and transferred to cryovials. It was then stored at -75°C. One set of plasma was used to determine the concentration of Compound 1 using a sandwich ELISA setup with the high affinity monoclonal αPAS antibody Avi-PA(S)1.1 and αhBNP antibody clone 50E1 (specificity for the C-terminus of hBNP32) to ensure high sensitivity and selectivity. The second set of plasma was used to determine plasma cGMP levels using an Abcam ELISA kit (cyclic GMP Complete ELISA kit (ab133052)|Abcam).

[0135] result Pharmacokinetics Data from Group 3, 0.2 mg / kg intravenous bolus Compound 1, ELISA assay of plasma samples can be fitted to a typical Bateman function. The results of the experiment are shown in FIG. [Table 1]

[0136] Data from the ELISA assay for Group 2 (0.9 mg / kg subcutaneous bolus Compound 1 plasma sample) showed a typical Bateman function biphasic pharmacokinetic profile and was fitted to a two-compartment model. The results of the analysis are shown in Figure 9 and Table 2. [Table 2]

[0137] The terminal half-life after subcutaneous administration was 14.8 hours, which is 27 times longer than that reported for the parent peptide, hBNP(1-32) (33 minutes, see FDA NDA #20-920 Pharmr P1 page 28, Drug Approval Package: Natrecor (Nesiritide) NDA #20-920 (fda.gov)).

[0138] Pharmacodynamics Subcutaneous bolus Compound 1 at 0.9 mg / kg produced sustained significant (P<0.05) reductions in systolic blood pressure (SBP), diastolic blood pressure (DBP) and calculated mean arterial pressure (MAP=DBP+[0.33+(HR×0.0012)]×[SBP]), but had no significant effect on heart rate (FIGS. 10 and 11). The mean reduction in MAP between 6 and 12 hours after dosing was 32.4±6.1 mmHg. Over the same 6-12 hour period, heart rate was reduced (not significant) by 7±13 beats per minute. MAP returned to baseline and vehicle control levels after 72 hours (FIG. 12).

[0139] An intravenous bolus dose of 0.2 mg / kg Compound 1 also produced a significant, transient decrease in blood pressure that returned to baseline 24 hours after dosing (FIG. 12).

[0140] Pharmacokinetics / Pharmacodynamics The effects on both MAP (FIG. 13) and the concentration of the biomarker, plasma cGMP (FIG. 14), reflected the plasma concentration of Compound 1 following administration of a 0.9 mg / kg subcutaneous bolus of Compound 1. The data in FIG. 13 also show that the 0.9 mg / kg subcutaneous bolus dose produced plasma concentrations over the study period that defined the compound's therapeutic window from subthreshold pharmacological effect levels to supramaximal effect levels.

[0141] array SEQ ID NO:1 SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:2 ASPAAPAPASPAAPAPSAPA SEQ ID NO:3 AAPASPAPAAPSAPAPAAPS SEQ ID NO:4 APSSPSPSAPSSPSPASPSS SEQ ID NO:5 SAPSSPSPSAPSSPSPASPS SEQ ID NO:6 SSPSAPSPSSPASPSPSSPA SEQ ID NO:7 AASPAAPSAPPAAASPAAPSAPPA SEQ ID NO:8 ASAAAPAAASAAASAPSAAA SEQ ID NO:9 APAAPAPAPAAPAPAPA SEQ ID NO:10 AAPAPAPAAPAPAPAAP SEQ ID NO:11 APPPAPPPAP SEQ ID NO:12 PAPPPAPPPA SEQ ID NO:13 AAPAAPAPPAAAPAAPAPPA SEQ ID NO:14 AAAAPAAAAAAAPAAA SEQ ID NO:15 CPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:16 SPCMVQGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:17 SPKCVQGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:18 SPKMCQGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:19 SPKMVCGSGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO:20 SPKMVQGCGCFGRKMDRISSSSGLGCKVLRRH SEQ ID NO: 21 (Synthetic gene fragment SapI-BNP32) AGGTAACATATGCCTGCCAGAAGAGCTCCTCAGCGCTCTTCTGCCAGTCCGAAAATGGTTCAAGGTAGCGGTTGTTTTGGTCGTAAAATGGATCGTATTAGCAGCAGCAGCGGTCTGGGTTGTAAAGTTCTGCGTCGTCATTAATAAGCTTGGGTTG SEQ ID NO: 22 (Synthetic gene fragment SapI-BNP3-32) AGGTAAcAtATGCCAGCCAGAAGAGCTCCTCAGCGCTCTTCTGCCAAAATGGTTCAAGGTAGCGGTTGTTTTGGTCGTAAAATGGATCGTATTAGCAGCAGCAGCGGTCTGGGTTGTAAAGTTCTGCGTCGTCATTAATAAGCTTGGGTTG SEQ ID NO: 23 (Synthetic gene fragment SapI-BNP6-32) ATTCGTTCAGGTAAcAtATGCCAGCCAGAAGAGCTCCTCAGCGCTCTTCTGCCCAAGGTAGCGGTTGTTTTGGTCGTAAAATGGATCGTATTAGCAGCAGCAGCGGTCTGGGTTGTAAAGTTCTGCGTCGTCATTAATAAGCTTGGGTTG SEQ ID NO:24 (Synthetic gene fragment BNP32) AGGTAAcAtATGAGTCCGAAAATGGTTCAAGGTAGCGGTTGTTTTGGTCGTAAAATGGATCGTATTAGCAGCAGCAGCGGTCTGGGTTGTAAAGTTCTGCGTCGTCATGCCAGAAGAGCTCCTCAGCGCTCTTCTGCCTAATAAGCTTGGGTTG SEQ ID NO:25 (Synthetic gene fragment BNP1-30) AGGTAAcAtATGAGTCCGAAAATGGTTCAAGGTAGCGGTTGTTTTGGTCGTAAAATGGATCGTATTAGCAGCAGCAGCGGTCTGGGTTGTAAAGTTCTGCGTGCCAGAAGAGCTCCTCAGCGCTCTTCTGCCTAATAAGCTTGGGTTG Array number 26 (PAS1.2(200)) GCCAGCCCTGCCGCACCTGCGCCCGCATCACCTGCGGCACCTGCACCTTCCGCCCCGGCTGCATCTCCTGCCGCACCCGCGCCTGCCAGCCCAGCTGCACCTGCCCCAAGTGCGCCAGCAGCATCCCCTGCCGCGCCTGCCCCCGCTAGTCCAGCGGCCCCAGCTCCATCTGCACCAGCTGCTAGCCCTGCTGCACCAGCTCCTGCTTCTCCCGCAGCCCCAGCGCCTTCTGCTCCCGCAGCCTCACCTGCGGCCCCGGCACCAGCATCTCCAGCGGCACCAGCACCTTCGGCCCCTGCTGCTAGCCCAGCAGCACCTGCGCCAGCCTCACCAGCTGCTCCCGCTCCTAGTGCCCCGGCGGCCTCGCCTGCTGCTCCTGCACCAGCTTCGCCAGCGGCACCGGCTCCTTCGGCGCCGGCTGCTTCACCAGCAGCACCTGCTCCAGCGTCCCCAGCGGCCCCTGCTCCAAGTGCTCCGGCTGCATCGCCTGCCGCTCCTGCTCCTGCATCCCCAGCTGCTCCAGCACCAAGCGCACCTGCCGCCTCACCAGCGGCGCCAGCACCCGCCAGCCCAGCAGCGCCTGCTCCATCCGCACCGGCGGCC Array number 27 (pD451-SR-PAS200-BNP32) SEQ ID NO: 28 (pD451-SR-PAS200-BNP3-32) SEQ ID NO: 29 (pD451-SR-PAS200-BNP6-32) SEQ ID NO: 30 (pD451-SR-BNP32-PAS200) SEQ ID NO: 31 (pD451-SR-BNP1-30-PAS200)

[0142] References Aghaabdollahian et al. (2019) Scientific Reports 9:2978. Cataliotti et al. (2007) Trends in Cardiovascular Medicine 17: 10 - 14. Chen et al. (2012) J Am Coll Cardiol. 60:2305 - 2312 doi:10.1016 / j.jacc.2012.07.056. Gengo et al. (1992) J Mol Cell Cardiol. 24:1361 - 1369. Gong et al. (2016) BMJ Open 6:e008545.doi:10.1136 / bmjopen - 2015 - 008545. Green and Sambrook (2012) Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Jefferies et al. (1996) J Med Chem 39: 2331 - 2338. Liu et al. (1997) J Clin Invest 99:1926 - 1935. McKie et al. (2016) Eur J Heart Fail. 2016 18:433 - 441 doi:10.1002 / ejhf.468. NCBI Reference Sequence NP_002512.1 O’Connor (2011) New England Journal of Medicine 365:32 - 43. Sabbah et al. (1991) Am.J.Physiol. 260:H1379 - H1384. Sabbah et al. (2000) Circulation 102:1990-1995. Wan et al. (2016) J Am Coll Cardiol HF 4:539-47. Xiong et al.(2015)PLOS ONE | DOI:10.1371 / journal.pone.0131326. U.S. Patent No. 5,114,923. U.S. Patent No. 5,674,710. U.S. Patent No. 6,586,396. U.S. Patent No. 6,974,861. U.S. Patent No. 7,179,790. PCT Patent Application Publication No. WO2009156481A1.

[0143] In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous objects attained.

[0144] Because various changes can be made in the methods and compositions described above without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted in an illustrative and not a limiting sense.

[0145] All references cited herein, including but not limited to patent publications and non-patent publications, and references cited therein, are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors, and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and relevance of the cited references.

[0146] As used herein, in certain embodiments, the term "about" or "approximately" when preceding a numerical value indicates a range of plus or minus 10% of the value. When a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of that range, to the tenth of the unit of the lower limit, and any other stated or intervening value within that stated range, is encompassed within the disclosure, unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and are encompassed within the disclosure, subject to any specifically excluded limit value in the stated range. When a stated range includes one or both of the upper and lower limits, ranges excluding one or both of those included upper and lower limits are also included in the disclosure.

[0147] As used in the specification and embodiments, unless clearly indicated to the contrary, the indefinite articles "a" and "an" should be understood to mean "at least one."

[0148] As used herein in the specification and embodiments, the term "and / or" should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are sometimes conjunctive and other times disjunctive. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so conjoined. Other elements, whether related or unrelated to those elements specifically identified by the "and / or" clause, may optionally be present. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), etc.

[0149] As used herein and in the embodiments herein, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" should be interpreted as inclusive, i.e., including at least one of, but more than one of, a number or list of elements, and optionally including additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the embodiments, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, as used herein, the term "or" should be interpreted as indicating exclusive alternatives (i.e., "one or the other, but not both") only when preceded by a term of exclusivity, such as "either," "one of," "only one of," or "exactly one of." As used in the present embodiments, "consisting essentially of" shall have its ordinary meaning as used in the field of patent law.

[0150] As used herein, and in embodiments herein, the phrase "at least one" should be understood in reference to a list of one or more elements to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether or not related to the specifically identified element. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer to, in one embodiment, at least one, optionally, two or more A, and no B (and optionally including elements other than B); in another embodiment, at least one, optionally, two or more B, and no A (and optionally including elements other than A); in yet another embodiment, at least one, optionally, two or more A, and at least one, optionally, two or more B (and optionally including other elements).

Claims

1. 1. A modified B-type natriuretic peptide (BNP) comprising a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% amino acid sequence identity to SEQ ID NO:1, the modified BNP further comprises a covalently attached polymer comprising an amino acid, the polymer inhibiting degradation and / or clearance of the BNP in a subject; A modified B-type natriuretic peptide (BNP), wherein said modified BNP retains vasorelaxant activity.

2. The modified BNP of claim 1 , which is truncated at the C-terminus and / or N-terminus of SEQ ID NO:

1.

3. The modified BNP of claim 2, wherein the truncated BNP is BNP2-32, BNP3-32, BNP4-32, BNP5-32, BNP6-32, BNP7-32, BNP8-32, BNP9-32, BNP10-32, BNP1-31, BNP1-30, BNP1-29, BNP1-28, BNP1-27, or BNP1-26.

4. The modified BNP of claim 1 , wherein the polymer comprises amino acids consisting of proline, alanine, and optionally serine residues (PAS).

5. The modified BNP of claim 4 , wherein the polymer comprises the amino acids proline and alanine.

6. The modified BNP of claim 4 , wherein the polymer comprises the amino acids proline, alanine, and serine.

7. The modified BNP of claim 5 , wherein the polymer comprises at least 100 amino acids.

8. The polymer is ASPAAPAPASPAAPAPSAPA (SEQ ID NO: 2), AAPASPAPSAPAPAPAAPS (SEQ ID NO: 3), APSSPSPSAPSSPSPAASPSS (SEQ ID NO: 4), SAPSSPSPSSAPSSPSPASPS (SEQ ID NO: 5), SSPSAPSPSSPASPSPSPSP (SEQ ID NO: 6), AASPAASAPPAAAASAPAAPSAPPA (SEQ ID NO: 7) ASAAAPAAAAASAAAASAPSAAA (SEQ ID NO: 8) APAAPAPAPAPAPAPA (SEQ ID NO: 9), AAPAPAPAPAPAPAAP (SEQ ID NO: 10), APPPAPPPAP (SEQ ID NO: 11), PAPPPAPPPA (SEQ ID NO: 12), AAPAAPAPPAAAAPAPAPPA (SEQ ID NO: 13) and AAAPAAAAAAAAPAAA (SEQ ID NO: 14) or a permuted or circularly permuted version or multimer of these sequences, either in whole or in part.

9. The modified BNP of claim 5 , wherein the polymer is terminated with proline.

10. The modified BNP of claim 5 , wherein the polymer comprises an extra alanine at the beginning or end of the polymer.

11. The modified BNP of claim 8 , wherein the polymer comprises at least 10 repeats of SEQ ID NO:

2.

12. The modified BNP of claim 8 , wherein the polymer comprises at least 20 repeats of SEQ ID NO:

2.

13. The modified BNP of claim 8 , wherein the polymer comprises at least 30 repeats of SEQ ID NO:

2.

14. The modified BNP of claim 8 , wherein the polymer comprises at least 40 repeats of SEQ ID NO:

2.

15. The modified BNP of claim 11 , wherein the polymer is terminated with proline.

16. The modified BNP of claim 11 , wherein the polymer comprises an extra alanine at the beginning or end of the polymer.

17. The modified BNP of claim 1 , wherein the polymer is covalently attached to the N-terminus and / or C-terminus of the BNP.

18. The modified BNP of claim 1 , wherein the polymer is covalently attached to at least one amino acid residue of the BNP.

19. 19. The modified BNP of claim 18, wherein the at least one amino acid residue covalently attached to the polymer is at residue 1, 2, 3, 4, 5, 6, 7, 8, or 9 of SEQ ID NO:

1.

20. 19. The modified BNP of claim 18, wherein the at least one amino acid residue covalently attached to the polymer is at residue 27, 28, 29, 30, 31 or 32 of SEQ ID NO:

1.

21. 2. The modified BNP of claim 1, comprising a cysteine ​​inserted between or substituting any of residues 1-9 or 27-32 of SEQ ID NO:1, said cysteine ​​being covalently attached to said polymer.

22. The modified BNP of claim 1 , further comprising a linker between the modified BNP and the polymer.

23. The modified BNP of claim 1 , wherein the modified BNP comprises two or more polymers.

24. 24. The modified BNP of claim 23, wherein said two or more polymers each independently comprise the amino acid proline, and optionally serine.

25. 24. The modified BNP of claim 23, wherein the two or more polymers include a polymer at a terminus of the BNP and a polymer linked to at least one amino acid residue of the BNP.

26. The modified BNP is P- (SEQ ID NO: 2) １０ -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO:2) １０ -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO:2) １０ -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) １０ -A (PAS bound to the C-terminal carboxy group), hBNP(1-30)- (SEQ ID NO:2) １０ -A (PAS bound to the carboxy group of the C-terminal arginine 30), P- (SEQ ID NO: 2) ２０ -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO:2) ２０ -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO:2) ２０ -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) ２０ -A (PAS bound to the C-terminal carboxy group), hBNP(1-30)- (SEQ ID NO:2) ２０ -A (PAS bound to the carboxy group of the C-terminal arginine 30), P- (SEQ ID NO: 2) ３０ -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO:2) ３０ -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO:2) ３０ -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) ３０ -A (PAS bound to the C-terminal carboxy group), hBNP(1-30)- (SEQ ID NO:2) ３０ -A (PAS bound to the carboxy group of the C-terminal arginine 30), P- (SEQ ID NO: 2) ４０ -A-hBNP(1-32) (PAS bound to the N-terminal amino group), P- (SEQ ID NO:2) ４０ -A-hBNP(3-32) (PAS attached to the alpha amino group of N-terminal lysine 3), P- (SEQ ID NO:2) ４０ -A-hBNP(6-32) (PAS attached to the N-terminus of glutamine 6), hBNP(1-32)- (SEQ ID NO: 2) ４０ -A (PAS bound to the C-terminal carboxy group), or hBNP(1-30)- (SEQ ID NO: 2) ４０ The modified BNP of claim 1, wherein said PAS is -A (PAS bound to the carboxy group of the C-terminal arginine 30).

27. The modified BNP of any one of claims 1 to 26 in a pharma- ceutically acceptable carrier.

28. 28. The modified BNP of claim 27 in a formulation that can be aerosolized.

29. A nucleic acid molecule encoding the modified BNP of claim 17.

30. A vector comprising the nucleic acid molecule of claim 29.

31. A cell comprising the vector of claim 30.

32. The cell of claim 31 , capable of expressing the modified BNP.

33. A composition for use in treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant, comprising a therapeutically effective amount of the modified BNP described in claim 27.

34. 34. The composition of claim 33, wherein the disease, disorder, or medical condition is a hematological disease, a neurological disease, a developmental disease, a urological disease, a reproductive disorder, a psychiatric disorder, a cancer, an autoimmune disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an infectious disease, a pulmonary disease, a cardiac disease, a vascular disease, or a metabolic disease.

35. The disease, disorder or medical condition is selected from the group consisting of anxiety, depression, post traumatic stress disorder, obesity, peripherally acting inflammatory bowel disease, irritable bowel syndrome, stress response, sleep disorders, addictive behavior, acute and chronic neurodegeneration, premature birth or pain, vasculitis and / or excessive angiogenesis in autoimmune disorders, systemic sclerosis, multiple sclerosis, Sjogren's disease, vascular and / or lymphatic malformations, left ventricular hypertrophy, portal hypertension, hepatic ascites, pulmonary hypertension, idiopathic pulmonary hypertension, atrial hypertension, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary fibrosis, DiGeorge syndrome, hereditary hemorrhagic telangiectasia, cavernous hemangiomas, cutaneous hemangiomas, lymphatic malformations, transplanted adenomas, atherosclerosis, vascular anastomoses, adipose tissue in obesity, 34. The composition of claim 33, wherein the disease is an allograft rejection, a skin disease, psoriasis, warts, allergic dermatitis, keloid scars, pyogenic granulomas, bullous diseases, Kaposi's sarcoma in AIDS patients, systemic sclerosis, an eye disease, persistent hyperplastic vitreous syndrome, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, pulmonary hypertension, asthma, nasal polyps, rhinitis, chronic airway inflammation and obstruction, cystic fibrosis, acute lung injury, bronchiolitis obliterans organizing pneumonia, a gastrointestinal disease, an inflammatory bowel disease, periodontal disease, ascites, peritoneal adhesions, liver cirrhosis, a reproductive system disease, endometriosis, uterine bleeding, ovarian cysts, ovarian hyperstimulation, a bone or joint disease, arthritis, synovitis, osteomyelitis, osteophyte formation, HIV-induced bone marrow angiogenesis, a kidney disease, or early diabetic nephropathy.

36. 34. The composition of claim 33, wherein the disease, disorder, or medical condition is a metabolic disease, a pulmonary disease, or heart failure.

37. 34. The composition of claim 33, wherein the disease, disorder, or medical condition is heart failure.

38. The composition of claim 33, wherein the administration is by injection.

39. The composition of claim 33, wherein the modified BNP is aerosolized and administered by inhalation.

40. A method for preparing the modified BNP of claim 17, comprising obtaining a cell of claim 32 and expressing the modified BNP.

41. A method for preparing the modified BNP of any one of claims 1 to 26, comprising expressing the modified BNP from a cell of claim 32, or producing a BNP derivative by solution or solid phase techniques, and then covalently attaching a polymer using chemical methods.

42. The method of claim 41, wherein the modified BNP of claim 25 is prepared by expressing the modified BNP of claim 17 in the cell and then covalently attaching a polymer to at least one amino acid residue of the modified BNP of claim 17.

43. Use of the modified BNP of any one of claims 1 to 26, the nucleic acid of claim 29, the vector of claim 30, or the cell of claim 32 for the manufacture of a medicament for the treatment of a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic, or vasorelaxant.

44. 44. The use according to claim 43, wherein the disease, disorder or medical condition is a metabolic disease, a pulmonary disease or heart failure.

45. 44. The use of claim 43, wherein the disease, disorder, or medical condition is heart failure.

Images